PhenoVista Biosciences raises growth capital

By The Science Advisory Board staff writers

January 19, 2022 -- PhenoVista Biosciences announced that it has secured funding from BroadOak Capital Partners. The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms to better understand neurodegenerative diseases, according to the company.

PhenoVista Biosciences provides customized imaging-based phenotypic assay services. It has developed assays for small and large biotechnology and pharmaceutical companies, as well as government agencies. To date, it has developed over 100 different phenotypic assays.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.